id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285982-1a5u7uux	Moss, Ronald B	Prospects for control of emerging infectious diseases with plasmid DNA vaccines	2009-09-07		.txt	text/plain	4227	202	42	The rapid manufacturing capabilities of DNA vaccines may be particularly important for emerging infectious diseases including the current novel H1N1 Influenza A pandemic, where pre-existing immunity is limited. Development in this area has greatly advanced over the years and human clinical trials of DNA vaccines have now been conducted against various infectious pathogens including the malaria parasite, dengue viruses, cytomegalovirus (CMV), Ebola virus, seasonal influenza viruses, avian or pandemic influenza viruses, West Nile virus (WMV), SARS coronavirus, hepatitis B virus, and HIV. Because the process of antigen production by host cells after DNA vaccination mimics the production of antigens during a natural infection, the resulting immune response is thought to be similar to the type induced by pathogens. Lastly, the first human clinical trial of a DNA vaccine formulated with Vaxfectin ® has been completed with plasmids that encode pandemic influenza virus antigens (H5N1).	./cache/cord-285982-1a5u7uux.txt	./txt/cord-285982-1a5u7uux.txt